Butylphthalide is currently more commonly used in the acute treatment of cerebral infarction, and is also one of the drugs recommended by the guidelines. The main effect is to promote the generation of collateral circulation, improve microcirculation, improve the energy supply of mitochondria, and have a certain anti-platelet aggregation effect. There are no fully equivalent alternatives to this medication, so if this medication is not available, you can also consider using Eurekulin. Eurekulin has no oral preparation, only intravenous preparation, is also a new class of drugs, is a kind of zymogen extracted from human urine, can also play the role of vasodilatation, improve the role of microcirculation. In the acute phase, the main mechanism is to promote the generation of collateral circulation, improve the blood supply of the ischemic area, save the ischemic semidarkness, so to a certain extent, it can replace the treatment of butylphthalide.